JACC Case Reports · 2022 · 12 citations · 5 references
Life SciencesOncologyPharmacotherapyAutoimmunityCancer ImmunologyImmunotherapyAutoimmune DiseasesCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune CheckpointsImmunosuppressionAcute Adverse EventsAutoimmune Adverse EventsHis-purkinje System DiseaseHis-purkinje System ElectrophysiologyImmune Checkpoint Inhibitor MyocarditisImmune Checkpoint Inhibitor TherapySerious Adverse EventsThird-degree Atrioventricular Block
Immune checkpoint inhibitors are associated with a myriad of autoimmune adverse events. We present a 70-year-old patient with renal-cell carcinoma treated with nivolumab/ipilimumab complicated with myocarditis and encephalitis in which gradual impairment of the His-Purkinje system progressed to complete atrioventricular block. Full recovery was achieved after treatment with corticosteroids and immunoglobulins. (Level of Difficulty: Intermediate.)
5
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider et al. · Journal of Clinical Oncology · 2018 · 3.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Spencer C. Wei, Wouter C. Meijers, Margaret L. Axelrod et al. · Cancer Discovery · 2020 · 272 citations · Full text